Walgreens launches next-day prescription delivery; AbbVie halts trial for cancer drug bought for $10.2 billion; Bill introduced in Senate to penalize pharma for gaming Medicaid.
CVS draws up plan to pass rebates to clients; Takeda shareholders approve Shire deal; Uber brings on two health executives.
Novartis hives treatment moves to late-stage trial; Amgen multiple myeloma antibody gets fast-tracked by FDA; ResMed to buy Propeller Health.
GlaxoSmithKline plans to buy cancer drug specialist company; MM&M unveils its inaugural class of Best Places to Work; GAO’s orphan drug program investigation finds flaws.
Bloomberg to donate $50m for action on opioids; Federal judge suggested rejecting CVS-Aetna merger; FDA plans move out of the U.K.
Bayer to cut 12,000 jobs; U.S. life expectancy drops again; Chinese government stops work on baby gene editing.
Amazon begins selling software to mine medical records; Juul develops product with less nicotine; Former Insys exec to plead guilty to bribery charges.
FDA to adjust 510(k) process; CMS proposes changes affecting insurers; MM&M launches first holiday contest.
Express Scripts pushes back on Novartis’ steep gene therapy price; WPP to merge two creative shops; Pfizer wins another cancer approval.
Walgreens, Humana in talks to take stakes in each other; Pfizer demands refund from Mississippi Senator Hyde-Smith; Government task force urges doctors to give PrEP to all at-risk patients.
Amazon-Berkshire-JPMorgan partnership hires measurement lead; CVS plans for post-Thanksgiving Aetna deal approval; FDA proposes reclassifying digital health tools.
Florida sues Walgreens, CVS over opioids; Results from experimental peanut allergy study; AstraZeneca plans ahead for next CEO.